Clinical Trial Update: Rapamycin for Prevention of Chronic Graft-Versus-Host Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated rapamycin (sirolimus) for the prevention of chronic graft-versus-host disease; the study was terminated and results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Yale University | Conditions: Graft Versus Host Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-02-03